top of page

Revolutionizing the treatment of 
ischemic stroke and heart attack,

re-establishing blood flow faster,

without bleeding, soon in the ambulance 

Thrombolytic Science (TSci) is a private, clinical stage, vascular medicine & biotech company

Our Focus

Current treatment options for patients experiencing a stroke or heart attack are limited and delay the
re-establishment of blood flow.

TSci is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.


TSci's bio-inspired solution is 

  • A low dose, efficacious, safer dual thrombolytic Rx

  • Based on a clinically validated mechanism

  • To be given on suspicion of a stroke or heart attack


Clinical Trials

TSci recently completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA / HisproUK dual regimen.  


TSci's dual regimen is currently being tested in a Phase 2 clinical trial in ischemic stroke patients.



tPA's biological role is limited to degrading the surface of the clot.

With TSci’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSci's compound, exclusively targets the now degraded clot and dissolves it.


Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow. 


TSci's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.



Management & Directors

Michael Woehler.jpeg

Alexis Wallace, MScEng, MBA
Chief Executive Officer,

Co-founder & Board member

Victor Gurewich, MD

Chief Scientific Officer,
Co-founder &
Board member

Michael Woehler, PhD

Non-Executive Chairman

of the Board


Advisory Board


Annalisa Jenkins, MBBS, FRCP

Chairman of the Court,

London School of Hygiene
Tropical Medicine

Non-Executive Chairman,

Cocoon Biotech


Gregory J. del Zoppo, M.D.

Professor of Medicine, Hematology

Adjunct Professor, Neurology, 

Washington University


James E. Muller, M.D.

Senior Lecturer,

Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx

1985 Nobel Peace Prize


C. Michael Gibson, M.D.

President & CEO,

Baim Institute
for Clinical Research

Professor of Medicine,

Harvard Medical School

Chairman & Founder, PERFUSE


May 22, 2023

Results of a Phase II trial of Thrombolytic Science's low dose dual therapy vs alteplase in mild stroke patients, published in JAMA Neuro.

  • No significant difference between groups in All ICH, i.e.: asymptomatic + symptomatic ICH, the primary endpoint.

  • Secondary endpoints show positive trends in favor of a safe, low dose dual therapy

    • No symptomatic ICH

    • Less disability

    • No fibrinogen depletion, i.e.: less risk of bleeding

Authors conclude further exploration in more severe stroke patients is warranted.

December 02, 2022

Thrombolytic Science submits an IND to FDA

October 29, 2021

Thrombolytic Science Awarded US Patent on its Novel Clot-dissolving Therapy


February 10, 2021

Thrombolytic Science Reinforces Its IP Portfolio with Patents in Europe, the Commonwealth of Independent States and Japan.  New Patents to Support Global Partnering of Novel Bio-inspired Clot-dissolving Therapy

October 30, 2019

Clinical milestone; first patients enrolled in Thrombolytic Science's Phase II ischemic stroke trial at Erasmus Medical School, Rotterdam, NL

September 5, 2018

NeurologyLive:  Phase II Trial of HisproUK, Low-Dose tPA Dual Therapy for Ischemic Stroke Initiated

November 15, 2017

Thrombolytic Science appoints Michael Woehler, PhD, Chairman of the board

September 18, 2017

Thrombolytic Science's first-in-man, randomized, double-blind, placebo-controlled Phase I clinical trial demonstrates safety and tolerability of TS01, a sequence of low doses of tPA and HisproUK



VIEW> Van der Ende, N et al.  Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small                        Bolus Alteplase for Ischemic Stroke, A Randomized Clinical Trial. JAMA Neurol. 2023. 



VIEW>  Gurewich V. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. JACC 2016.

VIEW>  Bogarty P, Brophy J. STEMI Treatment 2016: Is Outcome Improvement Stalling and If So, Why? DOI 2016.

VIEW>  Pannell R, Li S, Gurewich V. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA                     plus low-dose mutant proUK. PLoS One. 2015; 10(3):e0122018.

VIEW>  Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an                     effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999



Thanks for submitting!

Thrombolytic Science, LLC
One Broadway,  14 FL
Cambridge, MA 02142

bottom of page